Physitrack’s Q1 2026 report landed close to our overall expectations, maintaining the stable and profitable trajectory the Group has maintained for over a year. While headline revenue growth was modest, the underlying quality of earnings continues to improve through a strategic "SaaS-ification". The imminent launch of Remote Therapeutic Monitoring (RTM) and a potential US listing on OTCQX highlight Physitracks continued expansion into the North American market
LÄS MER
